Driven by Science,
Guided by Compassion

Company

Team

At Vico Therapeutics, our team is united by a shared vision: to bring hope and healing to those affected by rare neurological diseases. Comprised of leading scientists, experienced clinicians and passionate innovators, our team blends deep expertise in ASO therapies with a steadfast commitment to making a difference in patients’ lives.

Team

Leadership

Leadership micah mackison

Micah Mackison

Chief Executive Officer

Linkedin icon
Leadership nicole datson

Nicole Datson, PhD

Chief Scientific Officer/Site Head

Linkedin icon
Leadership scott schobel

Scott Schobel, MD

Chief Medical Officer

Linkedin icon
Leadership Prathana Khanna

Prarthana Khanna, PhD

Vice President, Corporate Business Development and Strategy

Linkedin icon

Team

Board of Directors

Bod luc dochez

Luc Dochez, PhD

(Chair and Founder)
Droia Ventures

Bod martijn kleijwegt

Martijn Kleijwegt

EQT Life Sciences

Bod felice verduyn

Felice Verduyn-Van Weegen

EQT Life Sciences

Bod remi droller

Remi Droller

Kurma Partners

Bod jeroen vangindertael.png

Jeroen Vangindertael, PhD

Ackermans & van Haaren

Bod amy schulman

Amy Schulman

Polaris Partners

Bod klaus breiner

Klaus Breiner, PhD

Pureos Bioventures

Bod josh mandel brehm

Josh Mandel-Brehm

(Co-Founder)
CAMP4 Therapeutics

Bod anders hinsby

Anders Hinsby, PhD

(Independent)
Muna Therapeutics

Bod micah mackison.png

Micah Mackison

CEO, Vico Therapeutics

Investors

Company Team Investors Logo Eqt Life Sciences
Company Team Investors Logo Kurma Partners
Company team investors logo ackermans van haaren
Company Team Investors Logo Droia
Company Team Investors Logo Pureos Bioventures
Company Team Investors Logo Polaris Partners
Company team investors logo seroba
Company team investors logo eurazeo

Recent News

Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington’s Disease
Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
See All Our News
Scroll to Top
Leadership
Leadership micah mackison

Leadership

Micah Mackison

Chief Executive Officer
Linkedin icon

Mr. Micah Mackison was appointed CEO of Vico Therapeutics in August 2022. Prior to this role, Micah served as Chief Business Officer and Executive Vice President of Strategy and Corporate Development at Locanabio, an RNA-targeted gene therapy company. At Locanabio, he was instrumental in setting strategy, raising capital and helping build an organization focused on genetic neurological diseases. Prior to Locanabio, Micah held several leadership positions in corporate development and strategy. He served as Senior Vice President, Corporate Development and Strategy at Assembly Biosciences where he led business development efforts. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, where he was focused on neuroscience. Prior to Lundbeck’s acquisition, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a neuroscience-focused company that launched the first product for Huntington’s disease.

Earlier in his career, Micah held financial roles at Eli Lilly and Pfizer. He earned a B.S. in Finance from the Kelley School of Business at Indiana University.

Leadership
Leadership nicole datson

Leadership

Nicole Datson, PhD
Chief Scientific Officer
Linkedin icon

Dr. Nicole Datson serves as Chief Scientific Officer of VICO, where she is responsible for discovery and non-clinical drug development. With more than twenty years of experience in preclinical research in both academia and industry, Nicole brings a strong background in molecular neuroscience to her position. Prior to joining VICO, she served as Senior Director Drug Discovery and Early Preclinical Development at BioMarin Nederland B.V. Previously, Nicole served as head of preclinical development at Prosensa Therapeutics B.V., developing antisense oligonucleotide-based therapies.

An internationally recognized expert, Nicole was a member of the international Huntington’s Disease Collaborative Research Group that cloned the gene for Huntington’s disease.
She obtained her PhD in molecular genetics from Leiden University, The Netherlands and held research staff positions as assistant professor at the Department of Medical Pharmacology and Human Genetics at Leiden University and Leiden University Medical Centre (LUMC). During her academic career, Nicole obtained several prestigious research grants and headed a research group in the field of molecular neuroscience where she focused on the identification of genes and pathways controlled by stress hormones in the brain as potential drug targets for treatment of stress-related brain disorders. She is the author of over 70 publications in peer-reviewed scientific journals in the field of molecular genetics, molecular biology and molecular neuroscience and RNA modulation.

Leadership
Leadership scott schobel

Leadership

Scott Schobel, MD

Chief Medical Officer
Linkedin icon

As Chief Medical Officer, Dr. Scott Schobel is responsible for clinical development programs at VICO including the lead asset VO659, an allele-preferential ASO targeting CAG repeat expansion diseases.  He brings extensive experience in neurological drug development, particularly in Huntington’s disease.

Previously, Scott held several leadership positions at Roche. As Group Medical Director and most recently Clinical Science Leader, he pioneered the development of clinical endpoints in Huntington’s disease research. He co-chaired a task force that generated a new research-based disease staging framework for Huntington’s disease based on underlying biology. He also clinically led the first ever huntingtin-lowering therapy Phase 3 program with tominersen. Prior to Roche, Scott was an assistant professor of clinical psychiatry at Columbia University Medical Center, where he studied hippocampal dysfunction across neurological and psychiatric diseases using a cross-species neuroimaging approach. He also served as medical director of Columbia University Medical Center’s Center of Prevention and Evaluation (COPE), a clinical service dedicated to the treatment and longitudinal study of teenagers and young adults at high risk for psychotic disorders.

Scott earned a BA in Japanese from the University of Minnesota, an MD from the University of North Carolina, and an M.S. from Columbia University.

Leadership
Leadership Prathana Khanna

Leadership

Prarthana Khanna, PhD

Vice President, Corporate Business Development and Strategy

Linkedin icon

Prarthana joins us most recently from Eli Lilly where she led business development transactions across the enterprise, including but not limited to M&A, in-licensing, out-licensing, and equity investments. Prior to Lilly, Prarthana helped establish the business development function at Akouos and was part of the deal team for the Lilly’s acquisition of the company.

Prarthana obtained a B.Sc. in Genetics from the University of Western Australia in Perth, followed by a PhD in Genetics in David Walt’s lab at the Tufts University School of Medicine in Boston.

After completing her B.Sc., Prarthana worked as a Research Technologist at the Mass General Institute for Neurodegenerative Disease (MIND) where she conducted research on the Huntington’s Disease Biomarkers Program and conducted pre-clinical research with Novartis on therapeutic agents for Huntington’s Disease. During her PhD, Prarthana also worked at the Tufts technology transfer office. After completing her PhD, Prarthana worked as a Senior BD Manager at the Harvard University Office of Technology Development, guiding Harvard faculty, post-docs, and grad students to commercialize their research. In this capacity, she negotiated licenses, options, and sponsored research agreements. After Harvard, Prarthana was at WuXi Biologics where she was the Head of Business Development and Licensing for North America and Europe and responsible for out-licensing WuXi Biologics’ proprietary platforms and antibodies.